Strategic Blueprint LLC Boosts Stock Holdings in Danaher Co. (NYSE:DHR)

Strategic Blueprint LLC lifted its holdings in Danaher Co. (NYSE:DHR) by 10.2% in the 2nd quarter, Holdings Channel.com reports. The firm owned 10,069 shares of the conglomerate’s stock after acquiring an additional 933 shares during the quarter. Strategic Blueprint LLC’s holdings in Danaher were worth $2,516,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Cary Street Partners Investment Advisory LLC raised its holdings in Danaher by 20.2% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock worth $2,112,000 after purchasing an additional 1,533 shares in the last quarter. Caden Capital Partners LP raised its stake in shares of Danaher by 12.4% during the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after acquiring an additional 15,313 shares in the last quarter. Legacy Financial Advisors Inc. lifted its position in Danaher by 2.4% during the fourth quarter. Legacy Financial Advisors Inc. now owns 2,377 shares of the conglomerate’s stock valued at $550,000 after acquiring an additional 55 shares during the last quarter. JARISLOWSKY FRASER Ltd grew its holdings in Danaher by 10.8% in the fourth quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock worth $132,524,000 after purchasing an additional 55,908 shares during the last quarter. Finally, HighPoint Advisor Group LLC acquired a new position in shares of Danaher during the fourth quarter worth $2,614,000. 79.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. TD Cowen boosted their price target on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Leerink Partners upped their price objective on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Evercore ISI dropped their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Finally, Royal Bank of Canada raised their price target on shares of Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $278.94.

Insiders Place Their Bets

In related news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,659 shares of company stock worth $11,042,433. Company insiders own 11.10% of the company’s stock.

Danaher Stock Down 1.0 %

Danaher stock opened at $266.06 on Thursday. The business’s 50-day moving average price is $259.22 and its 200 day moving average price is $254.78. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a market cap of $197.07 billion, a price-to-earnings ratio of 45.09, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the firm earned $2.05 EPS. The business’s quarterly revenue was down 2.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.